Atyr PHARMA INC (NASDAQ:ATYR – Get Free Report) Director Jane A. Gross acquired 3,750 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $4.00 per share, with a total value of $15,000.00. Following the completion of the acquisition, the director now owns 9,750 shares in the company, valued at approximately $39,000. The trade was a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Atyr PHARMA Stock Up 1.0 %
ATYR stock traded up $0.04 during trading on Monday, reaching $4.01. The stock had a trading volume of 2,054,474 shares, compared to its average volume of 826,408. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $3.65 and a 200 day moving average price of $3.09. The company has a market capitalization of $336.61 million, a P/E ratio of -4.27 and a beta of 0.98. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, equities analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.
Institutional Trading of Atyr PHARMA
Analysts Set New Price Targets
Several equities research analysts have commented on the company. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $18.60.
View Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Company Profile
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
- Five stocks we like better than Atyr PHARMA
- Investing In Automotive Stocks
- Can TikTok Stock Picks Really Make You Rich?
- How to Profit From Growth Investing
- The “Quality” Rotation: Back to Basics Investing
- The How And Why of Investing in Oil Stocks
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.